These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 34452097)

  • 1. Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature.
    Chatziralli I; Loewenstein A
    Pharmaceutics; 2021 Jul; 13(8):. PubMed ID: 34452097
    [No Abstract]   [Full Text] [Related]  

  • 2. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
    Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
    JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between Diabetic Retinopathy Severity and Oxygen Metabolism in Patients with Diabetic Macular Edema during Treatment with Intravitreal Aflibercept.
    Blindbæk SL; Peto T; Grauslund J
    Ophthalmic Res; 2020; 63(2):106-113. PubMed ID: 31715608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a systematic review and network meta-analysis.
    Fallico M; Maugeri A; Lotery A; Longo A; Bonfiglio V; Russo A; Avitabile T; Pulvirenti A; Furino C; Cennamo G; Barchitta M; Agodi A; Reibaldi M
    Acta Ophthalmol; 2021 Sep; 99(6):e795-e805. PubMed ID: 33326183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
    Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
    Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study.
    Chatziralli I; Dimitriou E; Theodossiadis G; Kazantzis D; Theodossiadis P
    Acta Diabetol; 2020 Oct; 57(10):1219-1225. PubMed ID: 32472172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy.
    Zhao Y; Singh RP
    Drugs Context; 2018; 7():212532. PubMed ID: 30181760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Vascular Endothelial Growth Factor Injections: The New Standard of Care in Proliferative Diabetic Retinopathy?
    Li X; Zarbin MA; Bhagat N
    Dev Ophthalmol; 2017; 60():131-142. PubMed ID: 28427072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy.
    Bahr TA; Bakri SJ
    Life (Basel); 2023 Apr; 13(5):. PubMed ID: 37240743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of clinical trials of anti-VEGF agents for diabetic retinopathy.
    Nicholson BP; Schachat AP
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):915-30. PubMed ID: 20174816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis.
    Simunovic MP; Maberley DA
    Retina; 2015 Oct; 35(10):1931-42. PubMed ID: 26398553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm?
    Wu L; Acón D; Wu A; Wu M
    Taiwan J Ophthalmol; 2019; 9(4):216-223. PubMed ID: 31942426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pan-retinal laser photocoagulation on intravitreal vascular endothelial growth factor concentration in proliferative diabetic retinopathy.
    Nišić F; Pidro A; Lepara O; Fajkić A; Mioković AP; Suljić E; Nišić A; Kovačević I
    Rom J Ophthalmol; 2022; 66(3):265-270. PubMed ID: 36349176
    [No Abstract]   [Full Text] [Related]  

  • 15. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
    Figueira J; Fletcher E; Massin P; Silva R; Bandello F; Midena E; Varano M; Sivaprasad S; Eleftheriadis H; Menon G; Amaro M; Ayello Scheer S; Creuzot-Garcher C; Nascimento J; Alves D; Nunes S; Lobo C; Cunha-Vaz J;
    Ophthalmology; 2018 May; 125(5):691-700. PubMed ID: 29395119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
    Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation.
    Royle P; Mistry H; Auguste P; Shyangdan D; Freeman K; Lois N; Waugh N
    Health Technol Assess; 2015 Jul; 19(51):v-xxviii, 1-247. PubMed ID: 26173799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-VEGF Injections vs. Panretinal Photocoagulation Laser Therapy for Proliferative Diabetic Retinopathy: A Systematic Review and Meta-Analysis.
    Macaron MM; Al Sabbakh N; Shami MZ; Akrobetu D; Bourdakos NE; Abdulsalam FAM; Nakanishi H; Than CA; Bakri SJ
    Ophthalmol Retina; 2024 Aug; ():. PubMed ID: 39128789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Widefield OCT-Angiography and Fluorescein Angiography Assessments of Nonperfusion in Diabetic Retinopathy and Edema Treated with Anti-Vascular Endothelial Growth Factor.
    Couturier A; Rey PA; Erginay A; Lavia C; Bonnin S; Dupas B; Gaudric A; Tadayoni R
    Ophthalmology; 2019 Dec; 126(12):1685-1694. PubMed ID: 31383483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions.
    Wubben TJ; Johnson MW;
    Am J Ophthalmol; 2019 Aug; 204():13-18. PubMed ID: 30878488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.